Invitation OXURION R&D Investor Day – Virtual 15 October 2020 at 5.30pm CET/ 11.30am ET October 8, 20200CommentsEN Read More
Save the date: Oxurion to host Virtual R&D Investor Day on 15 October 2020 October 5, 20200CommentsEN Read More
Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oct 2-4 September 29, 20200CommentsEN Read More
Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference September 14, 20200CommentsEN Read More
Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September September 11, 20200CommentsEN Read More
Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) September 1, 20200CommentsEN Read More
Oxurion NV appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer August 3, 20200CommentsEN Read More
Tussentijdse halfjaarresultaten 30 juni 2020 June 30, 20200CommentsTussentijdse halfjaarresultaten 30 juni 2020 Read More
Interim Financial Report Half-year results as of June 30, 2020 June 30, 20200CommentsInterim Financial Report Half-year results as of June 30, 2020 Read More
Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME, at Angiogenesis, Exudation, and Degeneration 2020 Conference February 9, 20200CommentsEN Read More
Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference February 5, 20200CommentsEN Read More
Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME January 7, 20200CommentsEN Read More
Annual Report – Financial results 2019 December 30, 20190CommentsAnnual Report - Financial results 2019 Read More
